Sales & Marketing News | pharmaphorum

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

What next for pharma as SCOTUS strikes down Trump tariffs?

The centrepiece of President Trump's economic strategy has been shattered after the Supreme Court ruled his sweeping tariffs are illegal.

News

FDA starts review of Regeneron's drug for rare disease FOP

Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?

News

Texas sues Sanofi, claiming kickbacks to doctors

Texas Attorney General Ken Paxton has filed a lawsuit against Sanofi, claiming the company bribed doctors to prescribe its medicines.

News

Hims & Hers buys Australian digital health firm for $1.15bn

Hims & Hers, facing a threat to its compounded medicines business, has ramped up its push for international expansion by buying Eucalyptus Health.

News

Scrabble lettering of Two and One on grass

Makary says FDA will "end two-trial dogma" for approvals

The FDA plans to adopt a new policy that will do away with the default requirement to base regulatory filings for new medicines on two pivotal trials.

FDA clears first all-oral combo for first-line CLL treatment

What next for pharma as SCOTUS strikes down Trump tariffs?

FDA starts review of Regeneron's drug for rare disease FOP

Texas sues Sanofi, claiming kickbacks to doctors

Hims & Hers buys Australian digital health firm for $1.15bn

Makary says FDA will "end two-trial dogma" for approvals

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks